Press Resease

Tumor Necrosis Factor Inhibitor Drugs Market by Product (Biosimilars, Cimzia, Simponi/Simponi Aria, Remicade, Enbrel and Humira); by Application (Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn’s Disease, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis and Other Applications); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2025

Published Date: 07-Nov-2019 Category: Pharmaceutical Report Format : PDF Pages: 126 Report Code: ZMR-5009 Status : Published

Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2025”. According to the report, global demand for tumor necrosis factor inhibitor drugs market was valued at approximately USD 40.23 billion in 2018, and is expected to generate revenue of around USD 42.08 billion by end of 2025, growing at a CAGR of around 0.7% between 2019 and 2025.

Description

The report covers forecast and analysis for the tumor necrosis factor inhibitor drugs market on a global and regional level. The study provides historic data from 2016 along with forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the tumor necrosis factor inhibitor drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the tumor necrosis factor inhibitor drugs market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the tumor necrosis factor inhibitor drugs market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the tumor necrosis factor inhibitor drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the tumor necrosis factor inhibitor drugs market on global and regional basis.

The study provides a crucial view on the tumor necrosis factor inhibitor drugs by segmenting the market based on product, application, distribution channel and region. All the segments of tumor necrosis factor inhibitor drugs market have been analyzed based on present and future trends and the market is estimated from 2018 to 2025.

Tumor necrosis factor (TNF) is a multifunctional protein cytokine produced by immune cells that causes inflammation in the body and plays important role in various cellular functions such as cell proliferation, differentiation, survival and death. Tumor necrosis factor inhibitors suppress body’s innate response to tumor necrosis factor (TNF). These inhibitors are used in treatment of inflammatory conditions such as psoriatic arthritis, ulcerative colitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis etc. These TNF inhibitor drugs are used in autoimmune disorders to avoid immune system attacking from healthy body cells.

The demand for tumor necrosis factor inhibitor drugs market is driven by increasing autoimmune disorders across the globe, increasing geriatric population base, promising pipelines, new product launches, increasing awareness among patients, increasing healthcare expenditure and increasing disposable income. However, emergence of new biosimilars as a result of loss of patent exclusivity in different regions, internal threat from biosimilars and intense competition from interleukin inhibitors are major factors that may hinder the market growth. Growing consumer preference for cost effective therapeutics with improved efficacy and safety will bring new growth opportunities for market players over the forecast period.

Based on product, global tumor necrosis factor inhibitor drugs market is bifurcated into Biosimilars, Cimzia, Simponi/Simponi Aria, Enbrel, Remicade and Humira. Humira product segment accounted for largest market share in 2018 and is expected to retain its dominance over the forecast period. This is due to its patent exclusivity in U.S. which will expire in 2023. Biosimilars product segment will experience maximum growth over the forecast period as a result of patent expiry and new launches.

Based on applications market is segmented into psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, ankylosing spondylitis and other applications. Rheumatoid arthritis application segment held dominating market share in 2018 driven by growing awareness, increasing incidence rate, and high treatment rate. Psoriatic arthritis and psoriasis application segments will witness highest growth rate over the forecast period.

The distribution channel segment of the TNF inhibitor drugs market is divided into specialty pharmacies, hospital pharmacies and online pharmacies. Largest distribution channel in 2018 was hospital pharmacies. Online pharmacies distribution channel segment is projected to witness rapid growth in the coming years.

North America dominated the global tumor necrosis factor inhibitor drugs market in 2018. Strong commercial sales, favorable reimbursement policies, presence of key players, large patient pool, and growing awareness are major factors driving the growth in this region. Europe was second largest regional market in terms of revenue share. Availability of developed infrastructure, increasing cases of autoimmune disorders, and growing awareness are some of factors that boost market growth in this region. Asia Pacific region will be the rapidly growing market for tumor necrosis factor inhibitor drugs. Healthcare infrastructure improvement, economic development, increasing geriatric population base, increasing disposable income and healthcare spending, growing awareness are important factors attributing to the rapid growth in this region. On the other hand Latin America will experience moderate growth in the coming years. Middle East and Africa will register slower growth in the years to come.

Major players in tumor necrosis factor inhibitor drugs market are Merck & co., Inc., Pfizer, Inc., Novartis International AG, UCB S.A., Johnson & Johnson Services, Inc., Amgen Inc., and AbbVie Inc. among others.

The report segment of global tumor necrosis factor inhibitor drugs market as follows:

Global Tumor Necrosis Factor Inhibitor Drugs Market: Product

  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • Biosimilars

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Hidradenitis Suppurativa
  • Others

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

Global Tumor Necrosis Factor Inhibitor Drugs Market: By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Tumor Necrosis Factor Inhibitor Drugs Market, 2016-2025 (USD Million)
    • 2.2. Tumor Necrosis Factor Inhibitor Drugs Market: Snapshot
  • Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market - Industry Analysis
    • 3.1. Tumor Necrosis Factor Inhibitor Drugs Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Product
      • 3.6.2. Market attractiveness analysis By Application
      • 3.6.3. Market attractiveness analysis By Distribution Channel
      • 3.6.4. Market attractiveness analysis By Region
  • Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Tumor Necrosis Factor Inhibitor Drugs Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Tumor Necrosis Factor Inhibitor Drugs Market - Product Analysis
    • 5.1. Global Tumor Necrosis Factor Inhibitor Drugs Market overview: By Product
      • 5.1.1. Global Tumor Necrosis Factor Inhibitor Drugs Market share, By Product,2018 and 2025
    • 5.2. Humira
      • 5.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Humira, 2016-2025 (USD Million)
    • 5.3. Enbrel
      • 5.3.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Enbrel, 2016-2025 (USD Million)
    • 5.4. Remicade
      • 5.4.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Remicade, 2016-2025 (USD Million)
    • 5.5. Simponi/Simponi Aria
      • 5.5.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Simponi/Simponi Aria, 2016-2025 (USD Million)
    • 5.6. Cimzia
      • 5.6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Cimzia, 2016-2025 (USD Million)
    • 5.7. Biosimilars
      • 5.7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Biosimilars, 2016-2025 (USD Million)
  • Chapter 6. Global Tumor Necrosis Factor Inhibitor Drugs Market -Application Analysis
    • 6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market overview: By Application
      • 6.1.1. Global Tumor Necrosis Factor Inhibitor Drugs Market share, By Application, 2018 and 2025
    • 6.2. Rheumatoid Arthritis
      • 6.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Rheumatoid Arthritis, 2016-2025 (USD Million)
    • 6.3. Psoriasis
      • 6.3.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Psoriasis, 2016-2025 (USD Million)
    • 6.4. Psoriatic Arthritis
      • 6.4.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Psoriatic Arthritis, 2016-2025 (USD Million)
    • 6.5. Crohn's Disease
      • 6.5.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Crohn's Disease, 2016-2025 (USD Million)
    • 6.6. Ulcerative Colitis
      • 6.6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Ulcerative Colitis Applications, 2016-2025 (USD Million)
    • 6.7. Ankylosing Spondylitis
      • 6.7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Ankylosing Spondylitis Applications, 2016-2025 (USD Million)
    • 6.8. Juvenile Idiopathic Arthritis
      • 6.8.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Juvenile Idiopathic Arthritis Applications, 2016-2025 (USD Million)
    • 6.9. Hidradenitis Suppurativa
      • 6.9.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Hidradenitis SuppurativaApplications, 2016-2025 (USD Million)
    • 6.10. Others
      • 6.10.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Other Applications, 2016-2025 (USD Million)
  • Chapter 7. Global Tumor Necrosis Factor Inhibitor Drugs Market -Distribution Channel Analysis
    • 7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market overview: By Distribution Channel
      • 7.1.1. Global Tumor Necrosis Factor Inhibitor Drugs Marketshare, By Distribution Channel, 2018 and 2025
    • 7.2. Hospital Pharmacies
      • 7.2.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Hospital Pharmacies, 2016-2025 (USD Million)
    • 7.3. Specialty Pharmacies
      • 7.3.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Specialty Pharmacies, 2016-2025 (USD Million)
    • 7.4. Online Pharmacies
      • 7.4.1. Global Tumor Necrosis Factor Inhibitor Drugs Market By Online Pharmacies, 2016-2025 (USD Million)
  • Chapter 8. Global Tumor Necrosis Factor Inhibitor Drugs Market - Regional Analysis
    • 8.1. Global Tumor Necrosis Factor Inhibitor Drugs Market overview: By Region
    • 8.1.1. Global Tumor Necrosis Factor Inhibitor Drugs Marketshare, By Region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Tumor Necrosis Factor Inhibitor Drugs Market, 2016-2025 (USD Million)
      • 8.2.2. North America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
      • 8.2.3. North America Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Application, 2016-2025 (USD Million)
      • 8.2.4. North America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S.Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.2.5.2. The U.S.Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S.Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. EuropeTumor Necrosis Factor Inhibitor Drugs Market2016-2025 (USD Million)
      • 8.3.2. Europe Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
      • 8.3.3. Europe Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
      • 8.3.4. Europe Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. U.K.Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.3.5.2. U.K.Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.3.6.2. France Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.3.6.3. France Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.3.7.2. Germany Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Application, 2016-2025 (USD Million)
        • 8.3.7.3. Germany Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of EuropeTumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.3.8.2. Rest of EuropeTumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Application, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Product,2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.4.5.2. China Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.4.5.3. China Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.4.6.2. Japan Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Application, 2016-2025 (USD Million)
        • 8.4.6.3. Japan Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.4.7.2. India Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Application, 2016-2025 (USD Million)
        • 8.4.7.3. India Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Product,2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market, 2016-2025 (USD Million)
      • 8.5.2. Latin America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
      • 8.5.3. Latin America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
      • 8.5.4. Latin America Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Product,2016-2025 (USD Million)
        • 8.5.5.2. Brazil Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Distribution Channel, 2016-2025 (USD Million)
      • 8.5.6. Rest of LatinAmerica
        • 8.5.6.1. Rest of LatinAmerica Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Product,2016-2025 (USD Million)
        • 8.5.6.2. Rest of LatinAmerica Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Product,2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market revenue, By Application, 2016-2025 (USD Million)
      • 8.6.4. The Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Marketrevenue, By Distribution Channel, 2016-2025 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1. Merck & co., Inc.
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Pfizer, Inc.
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Novartis International AG
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. UCB S.A.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Johnson & Johnson Services, Inc.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Amgen Inc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. AbbVie Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development

Methodology

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com